Treatment-by-Group in PROC MIXED and PROC GLM? [General Sta­tis­tics]

posted by mittyri – Russia, 2024-10-07 15:11 (64 d 23:33 ago) – Posting: # 24222
Views: 1,300

Hi BEQool,

❝ ❝ […] So you should prove why you modified your ANOVA to get F against Subject MS. […]

❝ I mean if the Group*Treatment is a between-subject factor, it should be, in my opinion, tested by using Subject MS as the denominator.


<IMHO>
Subject MS (nested within subgroup and sequence) is typically used to test other between-subject factors, like sequence or subgroup effects, not treatment-related effects. The subject MS usually captures variability between subjects but within their respective subgroups and sequences. Treatment-by-subgroup MS should generally be tested against the residual MS, because this residual error captures the variability within subjects that remains after accounting for treatment and subgroup effects.
If the subject MS is used as the denominator, this could lead to inflated F-values because the subject MS reflects between-subject variability, which is not appropriate for testing interactions involving the treatment effect
</IMHO>

❝ As already discussed, you think that if they had used MS Subject as the denominator, they would have probably written it here?


yes

❝ Which dataset are you talking about? Some random dataset or a specific one?


No preferences in exact dataset, but it would be good to test the dataset with unequal groups length

❝ And you are talking about testing Group*Treatment interaction with this dataset with both PROC MIXED and PROC GLM and to see if there is any difference?


yes, if possible please

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,336 posts in 4,902 threads, 1,665 registered users;
32 visitors (0 registered, 32 guests [including 5 identified bots]).
Forum time: 13:45 CET (Europe/Vienna)

I’m all in favor of the democratic principle
that one idiot is as good as one genius, but I draw the line
when someone takes the next step and concludes
that two idiots are better than one genius.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5